anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a processing technology of radix puerariae decoction pieces. Specifically, the processing technology comprises the following steps sequentially: selecting and cleaning medicines, washing the medicines, slicing the medicines, drying the medicines, conducting coarse grinding, conducting sterilizing, conducting secondary drying, conducting superfine grinding, totally mixing obtained materials, sub-packaging an obtained mixture, and packaging the sub-packaged mixture according to 10 bags per box and storing the boxes in a warehouse. The flow from the processing step to the sub-packaging step must be completed in a grade-D clean area. In a course of processing the radix puerariae decoction pieces, materials are mixed with a plurality of grinding media; under the action of mechanical force, the grinding media, through rotation and revolution motions, and meanwhile through a throwing motion, can become separate, so that the materials can enter spaces between the grinding media, and the grinding media can gather sometimes to cause intense collision. The materials between the grinding media, with the collision of the grinding medias, are exerted by two forces, namely pressure from front side and shearing force in a tangent direction. Under the two forces, the materials become torn and broken, so that an active ingredient is completely dissolved, with a dissolution rate higher than that of a conventional method by 3-8%. Therefore, after the radix puerariae decoction pieces provided by the invention are used, the efficacy can be fully absorbed by a human body, so that a good effect is achieved.
Open fractures are usually high-energy injuries that can lead to life-threatening multiple injuries. It is classified as an orthopaedic emergency, and successful treatment depends on a thorough assessment and prompt treatment of the patient and wound. With the rise in severe open tibia injuries, an ideal scoring system with high specificity and sensitivity for predicting limb salvage is required. A misdiagnosis can lead to unnecessary amputations or salvage operations. A variety of scoring methods have been described for limb salvaging. The Gustilo and Anderson classification system is still the most used. Following the original classification, typeIII injuries were subdivided into type-IIIA, which denoted adequate soft-tissue coverage of the fracture despite extensive skin loss, type-IIIB, which denoted extensive soft-tissue loss, periosteal stripping, and bone exposure; and type-IIIC, which denoted an open fracture with an associated arterial injury that required repair. It has the limitations of a low intra and inter-observer agreement rate, low specificity and sensitivity to salvage and ambulation, and an inability to predict functional results in the care of Type IIIB injuries. The Ganga Hospital Score (GHS) is an open injury score developed from a high-volume trauma center that treats more than 600 open lower-limb fractures each year, far higher than a typical major trauma center in the United Kingdom. Following three clinical trials, the score was developed and has been shown to accurately predict whether a limb can be saved or must be amputated. The scoring system's nature, which takes into account particular injuries to the bone, skin, and musculotendinous units, as well as comorbid factors, has also been expanded to advise wound treatment. In medicine, scoring systems are used to rate the severity of an illness, predict the outcome, and aid in management decisions. In open injuries, an ideal score would have a sensitivity of 100%, with all limbs requiring amputation scoring at or above the threshold value, and a specificity of 100%, with all limbs that can be preserved scoring below the threshold value. Because these injuries are frequently complex clinical conditions, this is challenging to achieve. Although it is preferable to err on the side of high specificity such that only a small percentage of salvageable limbs score over the amputation threshold, high sensitivity is also necessary to limit the number of secondary amputations.
In patients who are fully continent 6-weeks post-surgery (i.e., do not use pads in 24 hours), ePROMs are collected at 24 and 52 weeks, but no alarms or further actions are derived from them. Thus, treatment is provided according to routine clinical practice. Patients are not randomized.
The intervention supplement composed of Lactobacillus delbrueckii FSB, hydrogen-ated palm kernel oil, sodium caseinate, isolated soy protein, brown rice, inulin, digestive enzymes blend (lactase, protease, cellulase, lipase, amylase, pectinase, papain, and bromelain), galacto-oligosaccharides (GOS), and Bifidobacterium longum, powder form packaged in individual sachets (NattomeTM, Nattome, Kuala Lumpur, Malaysia). The dosage of FSB in each sachet was 1g.
The invention discloses a unmarked multi-site integrated expression glutaminase strain and a construction method thereof, belonging to the field of genetic engineering. The invention is characterized in that glutaminase genes are integrally expressed at 7 sites of 16S rDNA, nprB, nprE, aprE, spo0A, epr and bpr, and finally a multi-site non-resistance integrally expressed glutaminase strain BSM7 is obtained. After the BSM1 and the BSM7 obtained by the invention are fermented in a shake flask for 24 hours, the enzyme activities are respectively 40.5U/mL and 85.6U/mL, and the mutant enzyme activity is improved by 111.4%. The BSM7 strain is fed-batch fermented, and the highest enzyme activity is reached in about 32h, and is 375.6U/mL. Genetic stability analysis shows that the genetic stability of BSM7 is far greater than the stability of plasmid expression of the modified gene. The invention improves the application potential of glutaminase in food industry.
Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
An experimental group (GE) that after an initial evaluation and with their consent, will be subjected to a program that includes an intervention based on Mindfulness and an 8-week Education intervention, one day a week with a duration of 120 minutes. The sessions will be divided into two parts, a part of 60' of Mindfulness and another of 60' of Education. In the Mindfulness part, formal Meditation practices and conscious movements based on yoga will be carried out. In the Education part, participants will be instructed in concepts related to the basic neurophysiology of pain.
Aflibercept was administered 2mg per injection IVT in the study eye in Aflibercept 2Q8. Fixed dosing interval is 8 weeks (±3 days), modification of the treatment interval was not allowed.
A61P 1/00 medicine for treating digestive tract or digestive system diseases. There is no very good drug for treating colitis (ulcerative colitis or chronic inflammation of the colon). Some medicines have the problems of large side effect, easy relapse after treatment, long use time and the like. After the problems are met, through long-term observation and research, the specific traditional Chinese medicine formula has good curative effect on treating ulcerative colitis or chronic inflammation of colon. A Chinese medicinal composition is used for treating colitis (ulcerative colitis or chronic inflammation of colon). The specific formula is as follows: 3-10 g of coptis chinensis, 10-15 g of purslane, 10-15 g of dandelion, 25-35 g of salvia miltiorrhiza, 10-20 g of Chinese pulsatilla root, 10-15 g of sophora flower, 10-20 g of houttuynia cordata, 10-20 g of patrinia, 10-15 g of andrographis paniculata and 10-15 g of wild chrysanthemum.
PURPOSE:To obtain a water-in-oil type emulsified compsn. having stability for temp. by mixing a water swellable clay mineral, a quat. ammonium salt type cationic surface active agent, a specified organopolysiloxane, aqueous phase, and an oil phase contg. a specified high molecular silicone. CONSTITUTION:A water-in-oil type emulsified compsn. is produced by mixing a water-swellable clay mineral, a quat. ammonium salt type cationic surface active agent, a polyoxyalkylene modified organopolysiloxane expressed by formulas I, II, III, or IV (wherein R is 1-3C alkyl group; p is an integer 1-5; m is an integer 5-100; each t and y is an integer 0-50), an aqueous phase, and an oil phase contg. a high molecular silicone expressed by formula V (wherein R1 is methyl or phenyl group; R2 is methyl or OH group; n is an integer 3,000-20,000).
Enrolled patients were given roprostin (20 µg/kg subcutaneously once weekly) for at least 3 months, with discontinuation of roprostin for platelet counts ≥50 x 10\^9/L and continuation of roprostin for platelet counts \<50 x 10\^9/L. Responders were continued to 6 months. Responders continue to use the drug until 6 months.
PURPOSE: This is the first of three parts of the clinical practice guideline from the European Society of Intensive Care Medicine (ESICM) on resuscitation fluids in adult critically ill patients. This part addresses fluid choice and the other two will separately address fluid amount and fluid removal.
METHODS: This guideline was formulated by an international panel of clinical experts and methodologists. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was applied to evaluate the certainty of evidence and to move from evidence to decision.
RESULTS: For volume expansion, the guideline provides conditional recommendations for using crystalloids rather than albumin in critically ill patients in general (moderate certainty of evidence), in patients with sepsis (moderate certainty of evidence), in patients with acute respiratory failure (very low certainty of evidence) and in patients in the perioperative period and patients at risk for bleeding (very low certainty of evidence). There is a conditional recommendation for using isotonic saline rather than albumin in patients with traumatic brain injury (very low certainty of evidence). There is a conditional recommendation for using albumin rather than crystalloids in patients with cirrhosis (very low certainty of evidence). The guideline provides conditional recommendations for using balanced crystalloids rather than isotonic saline in critically ill patients in general (low certainty of evidence), in patients with sepsis (low certainty of evidence) and in patients with kidney injury (very low certainty of evidence). There is a conditional recommendation for using isotonic saline rather than balanced crystalloids in patients with traumatic brain injury (very low certainty of evidence). There is a conditional recommendation for using isotonic crystalloids rather than small-volume hypertonic crystalloids in critically ill patients in general (very low certainty of evidence).
CONCLUSIONS: This guideline provides eleven recommendations to inform clinicians on resuscitation fluid choice in critically ill patients.
PURPOSE:To provide the titled composition containing a specific substance derived from the reaction product of an amino acid and a sugar as a main component. CONSTITUTION:An amino acid (e.g. aspartic acid, glutamic acid, lysine, cystine, glycine, alanine, etc.) is made to react with a sugar (e.g. glucose, xylose, ribose, lactose, etc.) by heating the aqueous solution of the above components under nearly neutral pH condition at about 100 deg.C for a long period to cause the sufficient browning of the solution. A substance having a molecular weight of >=1,000, preferably >=5,000 is separated from the reaction product by membrane filtration method and dialysis. The objective antimutagenic composition can be produced by using the substance as a main component. The composition has extremely high antimutagenic effect against melanoidin which is a dehydrative condensation product having a molecular weight of >=1,000, especially >=5,000. A tasty food can be produced by using the above antimutagenic substance as a component.
Patients receive pembrolizumab IV over 30 minutes on day 1, paclitaxel IV over 1 hour and carboplatin IV over 1 hour on days 1, 7 and 14. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
Wearable devices can non-invasively monitor patients with chronic diseases. Sweat is an easily accessible biofluid for continuous sampling of analytes, including inflammatory markers and cytokines. We evaluated a sweat sensing wearable device in subjects with and without inflammatory bowel disease (IBD), a chronic inflammatory condition of the gastrointestinal tract. Participants with an IBD related hospital admission and a C-reactive protein level above 5 mg/L wore a sweat sensing wearable device for up to 5 days. Tumor necrosis factor-alpha (TNF-α) levels were continually assessed in the sweat via the sensor, and daily in the blood. A second cohort of healthy subjects without chronic diseases wore the device for up to 48 h. Twenty-eight subjects were enrolled. In the 16 subjects with IBD, a moderate linear relationship between serum and sweat TNF-α levels was observed (R2 = 0.72). Subjects with IBD were found to have a mean sweat TNF-α level of 2.11 pg/mL, compared to a mean value of 0.19 pg/mL in 12 healthy controls (p < 0.0001). Sweat TNF-α measurements differentiated subjects with active IBD from healthy subjects with an AUC of 0.962 (95% CI 0.894-1.000). A sweat sensing wearable device can longitudinally measure key sweat-based markers of IBD. TNF-α levels in the sweat of subjects with IBD correlate with serum values, suggesting feasibility in non-invasive disease monitoring.
OBJECTIVE: Magnetic resonance imaging (MRI) is the standard of care for evaluation of brain injury after hypoxic-ischemic encephalopathy (HIE) in term newborns. This study utilizes diffusion tensor imaging (DTI) to (1) identify infants at highest risk of development of cerebral palsy (CP) following HIE and to (2) identify regions of the brain critical to normal fidgety general movements (GMs) at 3 to 4 months of postterm. Absence of these normal, physiological movements is highly predictive of CP.
STUDY DESIGN: Term infants treated with hypothermia for HIE from January 2017 to December 2021 were consented for participation and had brain MRI with DTI after rewarming. The Prechtl's General Movements Assessment was performed at 12 to 16 weeks of age. Structural MRIs were reviewed for abnormalities, and DTI data were processed with the FMRIB Software Library. Infants underwent the Bayley Scales of Infant and Toddler Development III test at 24 months.
RESULTS: Forty-five infant families were consented; three infants died prior to MRI and were excluded, and a fourth infant was excluded due to diagnosis of a neuromuscular disorder. Twenty-one infants were excluded due to major movement artifact on diffusion images. Ultimately, 17 infants with normal fidgety GMs were compared with 3 infants with absent fidgety GMs with similar maternal and infant characteristics. Infants with absent fidgety GMs had decreased fractional anisotropy of several important white matter tracts, including the posterior limb of the internal capsule, optic radiations, and corpus callosum (p < 0.05). All three infants with absent fidgety GMs and two with normal GMs went on to be diagnosed with CP.
CONCLUSION: This study identifies white matter tracts of the brain critical to development of normal fidgety GMs in infants at 3 to 4 months of postterm using advanced MRI techniques. These findings identify those at highest risk for CP among infants with moderate/severe HIE prior to hospital discharge.
KEY POINTS: · HIE has devastating impacts on families and infants.. · Diffusion MRI identifies infants at highest risk for developing neurodevelopmental impairment.. · Normal general movements of infancy are generated by key white matter tracts..
The study design is a two-arm, randomized, controlled trial. The control arm will consist of standard conventional perioperative care. The intervention arm will consist of a protocol-driven ERAS program. The investigators believe that this information will be very useful because although there is a national interest in creating ERAS protocols for gynecology, there currently is very little published on the subject. Investigators hypothesize that those patients randomized to the ERAS protocol will have shorter lengths of hospital stay and complications, without increasing readmission rates. The investigators would like to publish the investigators' results and protocol as a resource for other institutions to adopt.
In addition to conventional chest physiotherapy programme, patients in this group will also receive creative dance based exercise training for 60 minutes, 2 times in a week for 8 weeks. All exercise sessions will be supervised in a clinic per week.
Electrotherapy program in our study 20 minutes, Hot-pack (HP) 20 minutes, 60-120 Hz frequency range 50-100 millisecond pulse time conventional TENS (Transcutaneous Electrical Nerve Stimulation) and 5 minutes 1.5 watt / cm2 treatment dosage 1 MHz ' ultrasound (US) treatment was applied. Exercise program; Eccentric and concentric strengthening and stretching of ECBR and ECBL muscles, terminal elbow flexion and extension, forearm pronation and supination exercises were given. Electrotherapy was given as 15 sessions for 6 weeks, 2 or 3 days a week, 1 session per day, and 30 sessions for 6 weeks, 5 days per week. Fifteen of these exercise sessions were supervised by the physiotherapist in the hospital and the remaining 15 patients did not come to the clinic on their own.
The invention relates to an oral ulcer external medicine. Oral ulcer is a phenomenon of excessive internal heat caused by human body disorder. Excessive internal heat causes symptoms such as ulcers in oral cavities, which are also known as oral ulcers. Because the affected part is in the oral cavity, great inconvenience is brought to patients. Pains are caused when people eats or talks. Because of the small problem, patients feel poor appetite. Because the problem is small, patients are not willing to go to hospital. Therefore, oral ulcers of a lot of patients are hard to cure for a long time. According to the invention, an external medicine prepared from traditional Chinese medicine can achieve a fast and safe effect in treating oral ulcers easily.
Each participant will receive either anagrelide, busulfan, interferon alfa/pegylated interferon alfa, or ruxolitinib as determined by investigator. All participants will be treated per respective approved product labels for up to 52 weeks. Participants receiving BAT for 52 weeks who stop responding to BAT are eligible to switch to bomedemstat and receive this for up to 152 weeks at the investigators discretion.
BACKGROUND: Preeclampsia and eclampsia are severe pregnancy disorders marked by hypertension and potential organ damage. The etiological basis of preeclampsia and eclampsia is not fully understood. Previous studies have revealed a link between sleep abnormality and preeclampsia/eclampsia, but the causal relationship remains unclear. In this study, we explored the genetic links between sleep and preeclampsia/eclampsia using genome-wide association study (GWAS) summary data and Mendelian randomization (MR) analysis.
METHODS: RNA sequence dataset GSE114691 was downloaded from the Gene Expression Omnibus database, comprising placental tissues from patients with preeclampsia and controls. Differential expression analysis was conducted with R (v4.2.3) and DESeq2 (v1.38.3). Gene set enrichment analysis (GSEA) was carried out using HTSanalyzeR2. GWAS summary data on preeclampsia/eclampsia and genetic markers for sleep abnormality were sourced from the FinnGen Consortium and IEU genetic databases. The Mendelian randomization analysis was conducted with TwoSampleMR (v0.6.2), and the inverse variance weighted (IVW) approach was employed as the principal method.
RESULTS: GSEA analysis revealed that the orexin receptor pathway showed heightened expression in the preeclampsia group versus controls. The random-effects IVW results showed that sleeplessness/insomnia has a genetic causal relationship with preeclampsia (OR = 2.08, 95% CI: 1.07-4.06, p = 0.0318), while sleep duration has evidence of regulating eclampsia (OR = 0.09, 95% CI: 0.01-0.67, p = 0.0187).
CONCLUSION: This study provides significant evidence for a genetic causal association between sleep abnormalities and preeclampsia/eclampsia. [Figure: see text].
This is a randomised, double-blind, placebo-controlled, multicentre, phase 2 study in Chinese adult outpatients with RSV infection. Approximately 160 eligible patients who have been recently diagnosed with RSV infection are planned to be enrolled into the study. Symptom scores of patients before and after treatment will be evaluated. Meanwhile, nasopharyngeal samples and blood samples will be collected for virological and pharmacokinetics evaluations. The evaluation of the safety and tolerability will include AE/SAE, vital signs, physical examination, laboratory examination and 12-lead ECGs. The total study duration for each patient will be 20 days.
PROBLEM TO BE SOLVED: To obtain the subject agent useful for the treatment of nervous lesion caused by external injury, etc., by using a specific fluorenone derivative having survival and growth promotionactions on cholinergic nerve cell of central nervous system, restoration and protection actions on peripheral nerve degeneration, etc., as an active component. SOLUTION: This agent contains at least one compound selected from a fluorenone derivative of the formula I (R<1> is H, OH, etc,; R<2> is H, a lower alkyl, etc.; (p) and (q) are each 1-4) and its salt as an active component. In the compounds of the formula I, e.g. 1,3,6,8-tetrapropyl-2,5-dihydroxyfluorenone is a new compound. The compound of the formula I can be produced e.g. by the cyclization reaction of a compound of the formula II in a hydrocarbon solvent having high boiling point (e.g. tetralin) at 150-200 deg.C. The amount of the compound of the formula I in a pharmaceutical preparation is usually 1-70wt.%. The daily administration rate of the compound of the formula I or its salt is usually 0.2-200mg per 1kg body-weight.
Accurately determining the metastatic status of sentinel lymph nodes (SLNs) through noninvasive imaging with high imaging resolution and sensitivity is crucial for cancer therapy. Herein, we report a dual-tracer-based NIR-II ratiometric fluorescence nanoplatform combining targeted and nontargeted moieties to determine the metastatic status of SLNs through the recording of ratio signals. Ratiometric fluorescence imaging revealed approximately 2-fold increases in signals in tumor-draining SLNs compared to inflamed and normal SLNs. Additionally, inflamed SLNs were diagnosed by combining the ratio value with the enlarged size outputted by NIR-II fluorescence imaging. The metastatic status diagnostic results obtained through NIR-II ratiometric fluorescence signals were further confirmed by standard H&E staining, indicating that the ratiometric fluorescence strategy could achieve distant metastases detection. Furthermore, the superior imaging quality of ratiometric probes enables visualization of the detailed change in the lymphatic network accompanying tumor growth. Compared to clinically available and state-of-the-art NIR contrast agents, our dual-tracer-based NIR-II ratiometric fluorescence probes provide significantly improved performance, allowing for the quick assessment of lymphatic function and guiding the removal of tumor-infiltrating SLNs during cancer surgery.